NCT05669079 - Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

August 1, 2026

Study Completion Date

November 1, 2026

Conditions

Poor Graft Function

Interventions

DRUG

decitabine

15 mg/m2 daily intravenously for consecutive 3 days

BIOLOGICAL

umbilical cord blood

MNC ≥ 3\*108 cells; HLA compatibility ≥ 5/6

DRUG

Granulocyte-colony stimulating factor

Granulocyte-colony stimulating factor will be used when absolute neutrophil count ≤ 1.5 × 109/L

DRUG

Recombinant human thrombopoietin / thrombopoietin receptor agonist

Recombinant human thrombopoietin or thrombopoietin receptor agonist will be used when platelet count ≤ 30 × 109/L

DRUG

Recombinant human erythropoietin

Recombinant human erythropoietin will be used when hemoglobin ≤ 85 g/L

All Listed Sponsors

lead

The First Affiliated Hospital of Soochow University

OTHER